We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

121 hedge funds and large institutions have $383M invested in Progenics Pharmaceuticals Inc in 2015 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 39 increasing their positions, 44 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more call options, than puts

Call options by funds: $1.02M | Put options by funds: $706K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1% less capital invested

Capital invested by funds: $385M → $383M (-$2.68M)

9% less funds holding

Funds holding: 133121 (-12)

11% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 44

50% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 24

Holders
121
Holders Change
-12
Holders Change %
-9.02%
% of All Funds
3.17%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
12
Increased
39
Reduced
44
Closed
24
Calls
$1.02M
Puts
$706K
Net Calls
+$310K
Net Calls Change
+$56K
Name Holding Trade Value Shares
Change
Change in
Stake
AA
51
ALPS Advisors
Colorado
$564K -$112K -17,116 -16%
BA
52
BlackRock Advisors
Delaware
$559K -$117K -17,777 -16%
ARTA
53
A.R.T. Advisors
New York
$551K +$590K +90,023 New
HCM
54
Highbridge Capital Management
New York
$479K +$195K +29,705 +61%
Wells Fargo
55
Wells Fargo
California
$463K +$366K +55,803 +282%
RhumbLine Advisers
56
RhumbLine Advisers
Massachusetts
$424K +$28.9K +4,405 +7%
HK
57
Horizon Kinetics
New York
$412K
ProShare Advisors
58
ProShare Advisors
Maryland
$406K +$42.5K +6,481 +11%
CS
59
Credit Suisse
Switzerland
$362K +$37.1K +5,652 +11%
CAM
60
CG Asset Management
New York
$359K -$1.22M -185,900 -76%
SC
61
Searle & Co
Connecticut
$349K -$98.3K -15,000 -20%
CHAM
62
Clear Harbor Asset Management
Connecticut
$348K -$5.31K -810 -1%
T. Rowe Price Associates
63
T. Rowe Price Associates
Maryland
$326K +$37.4K +5,700 +12%
MLICM
64
Metropolitan Life Insurance Company (MetLife)
New York
$308K +$31.6K +4,820 +11%
HCM
65
Hollencrest Capital Management
California
$307K +$184 +28 +0.1%
VRS
66
Virginia Retirement Systems
Virginia
$292K +$133K +20,300 +74%
SAM
67
Symphony Asset Management
California
$287K -$31.8K -4,850 -9%
NFA
68
Nationwide Fund Advisors
Ohio
$284K +$6.97K +1,063 +2%
State Board of Administration of Florida Retirement System
69
State Board of Administration of Florida Retirement System
Florida
$278K
CCMH
70
Cornerstone Capital Management Holdings
New York
$273K -$184K -28,000 -39%
Squarepoint
71
Squarepoint
New York
$253K +$271K +41,300 New
Ameriprise
72
Ameriprise
Minnesota
$233K -$1.33M -202,736 -84%
DekaBank Deutsche Girozentrale
73
DekaBank Deutsche Girozentrale
Germany
$221K +$3.28K +500 +1%
EGA
74
Eagle Global Advisors
Texas
$220K -$58.9K -8,980 -20%
UBS AM
75
UBS AM
Illinois
$209K -$18.4K -2,800 -8%

PGNX Hedge Fund Activity: Q4 2015 in Review

121 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2015, worth a combined $383M — down 0.7% from $385M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of PGNX and 12 opened new positions — a net loss of 12 holders — while 44 trimmed existing stakes and 39 added.

The largest buyer was Rice Hall James & Associates, adding an estimated $2.69M. The largest seller was State Street, cutting an estimated $14.1M.

  • 121 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2015, down from 133 in Q3 2015.
  • Funds reported $383M of Progenics Pharmaceuticals Inc stock for Q4 2015, down 0.7% quarter-over-quarter.
  • 12 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2015 and 24 closed out, a net change of -12 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q4 2015 was Rice Hall James & Associates, an estimated $2.69M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q4 2015 was State Street, an estimated $14.1M sold.

Based on aggregated 13F filings for Q4 2015.